X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs LUPIN LTD - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB LUPIN LTD DR. REDDYS LAB/
LUPIN LTD
 
P/E (TTM) x 27.5 17.0 162.0% View Chart
P/BV x 2.8 4.0 71.6% View Chart
Dividend Yield % 1.0 0.8 128.4%  

Financials

 DR. REDDYS LAB   LUPIN LTD
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-16
LUPIN LTD
Mar-16
DR. REDDYS LAB/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs4,3832,127 206.1%   
Low Rs2,7501,294 212.5%   
Sales per share (Unadj.) Rs920.1304.1 302.6%  
Earnings per share (Unadj.) Rs126.150.4 250.2%  
Cash flow per share (Unadj.) Rs183.060.7 301.5%  
Dividends per share (Unadj.) Rs20.007.50 266.7%  
Dividend yield (eoy) %0.60.4 127.9%  
Book value per share (Unadj.) Rs685.8243.8 281.3%  
Shares outstanding (eoy) m170.61450.58 37.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.95.6 68.9%   
Avg P/E ratio x28.333.9 83.3%  
P/CF ratio (eoy) x19.528.2 69.1%  
Price / Book Value ratio x5.27.0 74.1%  
Dividend payout %15.914.9 106.6%   
Avg Mkt Cap Rs m608,481770,740 78.9%   
No. of employees `00021.716.4 132.5%   
Total wages/salary Rs m31,87421,077 151.2%   
Avg. sales/employee Rs Th7,244.48,379.6 86.5%   
Avg. wages/employee Rs Th1,470.91,289.0 114.1%   
Avg. net profit/employee Rs Th992.81,388.7 71.5%   
INCOME DATA
Net Sales Rs m156,978137,016 114.6%  
Other income Rs m2,6931,877 143.5%   
Total revenues Rs m159,671138,893 115.0%   
Gross profit Rs m34,58737,535 92.1%  
Depreciation Rs m9,7054,635 209.4%   
Interest Rs m824446 184.7%   
Profit before tax Rs m26,75134,330 77.9%   
Minority Interest Rs m0-88 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,23711,536 45.4%   
Profit after tax Rs m21,51422,707 94.7%  
Gross profit margin %22.027.4 80.4%  
Effective tax rate %19.633.6 58.3%   
Net profit margin %13.716.6 82.7%  
BALANCE SHEET DATA
Current assets Rs m118,20197,790 120.9%   
Current liabilities Rs m68,36853,872 126.9%   
Net working cap to sales %31.732.1 99.0%  
Current ratio x1.71.8 95.2%  
Inventory Days Days6085 70.8%  
Debtors Days Days97121 79.9%  
Net fixed assets Rs m72,26586,379 83.7%   
Share capital Rs m853901 94.7%   
"Free" reserves Rs m111,548105,735 105.5%   
Net worth Rs m117,009109,844 106.5%   
Long term debt Rs m10,69053,739 19.9%   
Total assets Rs m200,104224,378 89.2%  
Interest coverage x33.577.9 42.9%   
Debt to equity ratio x0.10.5 18.7%  
Sales to assets ratio x0.80.6 128.5%   
Return on assets %11.210.3 108.2%  
Return on equity %18.420.7 88.9%  
Return on capital %21.621.2 101.8%  
Exports to sales %46.349.1 94.3%   
Imports to sales %9.07.4 120.2%   
Exports (fob) Rs m72,61867,244 108.0%   
Imports (cif) Rs m14,05010,199 137.8%   
Fx inflow Rs m75,40571,405 105.6%   
Fx outflow Rs m27,11517,807 152.3%   
Net fx Rs m48,29053,598 90.1%   
CASH FLOW
From Operations Rs m40,476-3,690 -1,097.0%  
From Investments Rs m-19,421-69,434 28.0%  
From Financial Activity Rs m-17,00958,126 -29.3%  
Net Cashflow Rs m4,046-14,998 -27.0%  

Share Holding

Indian Promoters % 25.5 46.6 54.7%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 5.4 11.3 47.8%  
FIIs % 35.3 31.9 110.7%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.1 151.5%  
Shareholders   75,885 98,259 77.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ORCHID PHARMA LTD  STERLING BIOTECH  JUBILANT LIFE SCIENCES  VENUS REMEDIES  IPCA LABS  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Tata Global Beverages Surges 8.3%(Closing)

Indian share markets snapped their losing streak of last week and finished the trading day on a strong note due to strong buying momentum in FMCG stocks, metal stocks and auto stocks.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 16, 2017 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS